On the stock market since 2017, it operates in the world of health and science. It has 141 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 86% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $82M a year. A small number, but proof the product has real buyers.
There is $189.5M in the vault; even if every debt were paid off, $179.5M would remain.
A loss of $50.9M against $82M in annual sales.
Over the last 12 months, executives reported 68 sells against just 13 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, JNCE sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: JNCE is a high-risk stock — not yet profitable, and its future rides on its product catching on.